Vmbook Online ordering

Biotechnology

Sure, here is general information about a public company in the biotechnology industry with the stock symbol NTLA:

Company: Intellia Therapeutics, Inc.

Stock symbol: NTLA

Exchange: NASDAQ

Intellia Therapeutics, Inc. is a biotechnology company that specializes in the development of CRISPR-Cas9 gene editing technologies for therapeutic applications. The company's mission is to revolutionize the treatment of diseases by leveraging the CRISPR-Cas9 technology to create safe and effective gene-based medicines.

Earnings:

* Revenue: $2.47 million (2022)

* Net income: -$122.84 million (2022)

Growth:

* Revenue growth: 31.3% (2022 vs. 2021)

* Income growth: -32.7% (2022 vs. 2021)

Other key financial metrics:

* Cash and cash equivalents: $394.7 million (December 31, 2022)

* Total assets: $584.9 million (December 31, 2022)

* Total liabilities: $127.1 million (December 31, 2022)

Research and Development (R&D) Expenses:

* R&D expenses were $84.2 million for the year ended December 31, 2022.

Pipeline:

Intellia Therapeutics' pipeline includes several CRISPR-Cas9 gene editing product candidates in various stages of development, including:

1. NTLA-2001: An investigational CRISPR-Cas9 gene editing therapy for the treatment of sickle cell anemia and beta-thalassemia.

2. NTLA-2002: An investigational CRISPR-Cas9 gene editing therapy for the treatment of severe hemophilia A.

3. NTLA-2003: An investigational CRISPR-Cas9 gene editing therapy for the treatment of rare genetic diseases, including Fabry disease.

4. NTLA-2004: An investigational CRISPR-Cas9 gene editing therapy for the treatment of muscular dystrophy.

Partnerships and Collaborations:

Intellia Therapeutics has established partnerships and collaborations with several leading institutions and companies, including:

1. CRISPR Therapeutics: A collaboration focused on the development of CRISPR-Cas9 gene editing therapies for the treatment of sickle cell anemia and beta-thalassemia.

2. Novartis: A collaboration focused on the development of CRISPR-Cas9 gene editing therapies for the treatment of sickle cell anemia and beta-thalassemia.

3. Bio-Techne: A collaboration focused on the development of CRISPR-Cas9 gene editing therapies for the treatment of Fabry disease.

It's worth noting that the information above is subject to change and may not reflect the current state of the company. It's important to do your own research and due diligence before making any investment decisions.